Primary biliary cirrhosis is chronic, progressive, autoimmune, cholestatic liver disease more common in middle-aged women. It is characterized by destruction of small to medium bile ducts, leading to cholestasis and frequently, end-stage liver disease.
Diagnostic features are chronic biochemical cholestasis, presence of antimitochondrial antibodies and the characteristic liver biopsy findings.
At present, the diagnosis is most often made in an asymptomatic patient who presents with abnormal lab results on a routine checkup or as part of workup for an associated illness.
During pregnancy, there is generalized relaxation of smooth muscle resulting in relaxa¬tion of the oesophageal sphincter, reduced gastric peristalsis, and delayed gastric emp¬tying. Small and large bowel transit times are increased. There is increased blood flow to the liver and increased production of fibrinogen, transferrin and many other binding proteins. Reference ranges for many liver function tests are altered. Gestation-specific alkaline phosphatase is increased, mainly from increased placental production, and aminotransferases and γ-glutamyltransferase are reduced.
New drug applications approved by US FDA as of 16 - 31 July 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.